Haemonetics Corporation (HAE)
Company Info
US4050241003
405024100
May 9, 1991
Highlights
$3.26B
$3.32
20.43
1.17
$1.36B
$748.96M
$279.98M
$55.30 - $94.99
$91.10
13.87%
6.83
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Haemonetics Corporation (HAE) returned -13.28% year-to-date (YTD) and -20.01% over the past 12 months. Over the past 10 years, HAE returned 4.83% annually, underperforming the S&P 500 benchmark at 10.85%.
HAE
-13.28%
7.44%
-22.59%
-20.01%
2.29%
-9.20%
4.83%
^GSPC (Benchmark)
0.51%
6.15%
-2.00%
12.92%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of HAE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -11.57% | -5.14% | -2.98% | -0.83% | 7.44% | -13.28% | |||||||
| 2024 | -10.58% | -4.55% | 16.95% | 7.73% | -8.56% | -1.61% | 8.85% | -16.07% | 6.35% | -11.47% | 22.92% | -10.74% | -8.69% |
| 2023 | 7.57% | -8.07% | 6.40% | 1.16% | 1.06% | 0.64% | 8.34% | -2.72% | -0.17% | -4.86% | -5.12% | 5.74% | 8.72% |
| 2022 | -8.84% | 19.36% | 9.55% | -19.85% | 24.85% | 3.04% | 6.61% | 7.97% | -1.33% | 14.75% | 0.42% | -7.81% | 48.28% |
| 2021 | -3.76% | 10.68% | -12.25% | -39.41% | -16.06% | 18.03% | -8.78% | 3.22% | 12.49% | -2.66% | -25.41% | 3.49% | -55.33% |
| 2020 | -6.54% | 0.88% | -8.00% | 14.17% | -3.60% | -18.34% | -2.12% | 2.28% | -2.69% | 15.86% | 11.63% | 5.23% | 3.35% |
| 2019 | -1.14% | -12.17% | 0.70% | -0.23% | 11.13% | 24.07% | 1.45% | 9.38% | -5.53% | -4.29% | -0.11% | -4.73% | 14.84% |
| 2018 | 11.31% | 9.67% | 3.19% | 6.67% | 15.77% | -0.74% | 8.88% | 14.34% | 2.63% | -8.82% | 2.69% | -6.74% | 72.26% |
| 2017 | -0.85% | -6.35% | 8.68% | 3.23% | -2.63% | -3.16% | 4.15% | 4.60% | 4.30% | 6.00% | 21.53% | 0.48% | 44.48% |
| 2016 | -1.86% | 1.39% | 9.04% | -7.29% | -13.66% | 3.54% | 4.59% | 22.56% | -2.56% | -7.73% | 18.62% | 1.44% | 24.69% |
| 2015 | 5.83% | 12.27% | 1.03% | -9.77% | 1.95% | 0.10% | -3.26% | -9.75% | -10.50% | 4.52% | -4.56% | -0.00% | -13.84% |
| 2014 | -10.06% | -3.72% | -10.66% | -6.84% | 12.19% | 3.58% | 0.82% | 0.34% | -2.16% | 8.02% | -2.09% | 1.33% | -11.18% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of HAE is 20, meaning it’s performing worse than 80% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Haemonetics Corporation (HAE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Haemonetics Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Haemonetics Corporation was 68.62%, occurring on Jan 27, 2022. The portfolio has not yet recovered.
The current Haemonetics Corporation drawdown is 51.46%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -68.62% | Feb 9, 2021 | 245 | Jan 27, 2022 | — | — | — |
| -60.48% | Nov 26, 2001 | 405 | Jul 7, 2003 | 419 | Mar 4, 2005 | 824 |
| -53.54% | Dec 31, 1993 | 326 | Apr 17, 1995 | 1201 | Jan 18, 2000 | 1527 |
| -46.33% | Aug 19, 2019 | 147 | Mar 18, 2020 | 224 | Feb 5, 2021 | 371 |
| -42.96% | Jul 26, 2013 | 706 | May 13, 2016 | 349 | Oct 2, 2017 | 1055 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Haemonetics Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Haemonetics Corporation, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 1.6% positive surprise.
Valuation
The Valuation section provides an overview of how Haemonetics Corporation is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for HAE, comparing it with other companies in the Medical Instruments & Supplies industry. Currently, HAE has a P/E ratio of 20.4. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for HAE compared to other companies in the Medical Instruments & Supplies industry. HAE currently has a PEG ratio of 1.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for HAE relative to other companies in the Medical Instruments & Supplies industry. Currently, HAE has a P/S ratio of 2.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for HAE in comparison with other companies in the Medical Instruments & Supplies industry. Currently, HAE has a P/B value of 4.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |